Key Documents

View All Documentation

M2319

Mefloquine hydrochloride

Name: Mefloquine hydrochloride
Brand: SIGMA

≥98% (HPLC), Cx36 and Cx50 blocker, powder

Synonym(s):

(AS)-rel-a-(2R)-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol monohydrochloride

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₇H₁₇ClF₆N₂O

CAS Number:

51773-92-3

Molecular Weight:

414.77

NACRES:

NA.77

PubChem Substance ID:

24724536

UNSPSC Code:

12352202

EC Number:

257-412-0

MDL number:

MFCD00797519

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Storage condition:

desiccated

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Mefloquine hydrochloride, ≥98% (HPLC), powder

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white

solubility

DMSO: soluble 38 mg/mL, H₂O: insoluble

SMILES string

Cl[H].[H][C@@]1(CCCCN1)[C@@H](O)c2cc(nc3c(cccc23)C(F)(F)F)C(F)(F)F

InChI

1S/C17H16F6N2O.ClH/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11;/h3-5,8,12,15,24,26H,1-2,6-7H2;1H/t12-,15+;/m1./s1

InChI key

WESWYMRNZNDGBX-YLCXCWDSSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecules

Application

Mefloquine hydrochloride has been used:

to treat cochlear organotypic cultures with various doses to evaluate its role in cellular pathway involved in apoptosis
in screening for in vitro antischistosomal activity
in cytotoxicity assay of glioblastoma cells

Biochem/physiol Actions

Mefloquine is broadly used as an antimalarial drug. It inhibits 80S ribosomes of Plasmodium. It has numerous side effects like anxiety, dizziness, tremor, headache, and hearing loss. Mefloquine damages cochlear and vestibular hair cells through apoptosis. It also damages spiral ganglion neurons, degenerates cortical neuron and disrupts neuronal calcium homeostasis.

Blocker of gap junction channels Cx36 and Cx50.

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000294579

0000196117

0000134876

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.

Mahadeo A Sukhai et al.

The Journal of clinical investigation, 123(1), 315-328 (2012-12-04)

Despite efforts to understand and treat acute myeloid leukemia (AML), there remains a need for more comprehensive therapies to prevent AML-associated relapses. To identify new therapeutic strategies for AML, we screened a library of on- and off-patent drugs and identified

Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.

Rithea Leang et al.

Antimicrobial agents and chemotherapy, 57(2), 818-826 (2012-12-05)

We describe here the results of antimalarial therapeutic efficacy studies conducted in Cambodia from 2008 to 2010. A total of 15 studies in four sentinel sites were conducted using dihydroartemisinin-piperaquine (DP) for the treatment of Plasmodium falciparum infection and chloroquine

Identification of plumbagin and sanguinarine as effective chemotherapeutic agents for treatment of schistosomiasis

Zhang SM and Coultas KA

International Journal for Parasitology, Drugs and Drug Resistance, 3(11), 28-34 (2013)

Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A

Rahim SAA, et al.

British Journal of Cancer, 117(6), 813-813 (2017)

Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development.

Sophie Zaloumis et al.

Malaria journal, 11, 303-303 (2012-08-31)

Mechanistic within-host models relating blood anti-malarial drug concentrations with the parasite-time profile help in assessing dosing schedules and partner drugs for new anti-malarial treatments. A comprehensive simulation study to assess the utility of a stage-specific pharmacokinetic-pharmacodynamic (PK-PD) model for predicting

View All Related Papers

Global Trade Item Number

SKU	GTIN
M2319-100MG	04061834041894

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service